Phase 2 Study of SBRT Plus Tislelizumab and Regorafenib in Unresectable or Oligometastatic HCC

NCT05917431 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

39

Enrollment

OTHER

Sponsor class

Conditions

Unresectable Hepatocellular Carcinoma
Oligometastatic Disease

Interventions

COMBINATION_PRODUCT: SBRT plus tislelizumab and regorafenib

Sponsor

Peking University Cancer Hospital & Institute